Advertisment

Revolutionary Cancer Vaccine Nears Phase 3 Trial: A Personalized Approach to Cancer Treatment

author-image
Ayanna Amadi
New Update
NULL

Revolutionary Cancer Vaccine Nears Phase 3 Trial: A Personalized Approach to Cancer Treatment

Advertisment

A New Hope in Cancer Treatment

Advertisment

Dr. Thomas Wagner, the founder of Orbis Health Solutions, has made a groundbreaking development in the fight against cancer. He and his team have pioneered a personalized cancer vaccine that leverages the power of a patient's immune system to combat the disease. Known as the tumor lysate particle only (TLPO) vaccine, this novel treatment has shown promising results in Phase 2 clinical trials, particularly for patients with advanced melanoma.

Nearly 95% of patients administered with the vaccine were still alive three years after starting the treatment, and impressively, 64% were still disease-free. This new vaccine has been hailed for its minimal side effects, which typically include redness or pain at the injection site, fever, and fatigue.

FDA Greenlights Phase 3 Clinical Trial

Advertisment

The FDA has given the go-ahead for the TLPO vaccine to proceed to a Phase 3 clinical trial. The goal for this trial is to enroll around 500 people to further test the vaccine's efficacy and safety. However, financial constraints have posed challenges to the progress of the trial.

Despite these hindrances, Orbis Health Solutions has initiated a basket trial, which allows the vaccine to be tested on anyone with a solid tumor. This trial is a significant step forward as it broadens the scope of patients who could potentially benefit from the vaccine.

First Patient's Experience: A Ray of Hope

Advertisment

The first person to participate in this basket trial was Catie King, an Asheville, North Carolina native, who was diagnosed with ovarian cancer six years ago. Catie reported feeling great after her initial round of treatment, offering hope to countless others battling with cancer.

As patient zero of this innovative cancer vaccine trial, Catie's journey is far from over. She is set to receive more injections and booster shots in the coming months. Her experience with the vaccine could potentially save many lives, providing invaluable data and feedback for the trial.

Immunotherapy: A Game-Changer in Cancer Treatment

Advertisment

Orbis Health Solutions is at the forefront of immunotherapy research, a revolutionary approach to cancer treatment. The TLPO vaccine works by making tumor cells appear as pathogens, stimulating the immune system to eliminate them. Each patient's vaccination is personalized, utilizing samples from their own tumors to create the vaccine.

With the successful completion of a large Phase II B trial, the company is now preparing for the Phase III Registrational Trial. Although the treatment costs more than $10,000 per patient, participants in the trials are not charged.

The success of the Phase 3 clinical trial and FDA approval will be a determining factor in the wider availability and use of the TLPO vaccine. With promising results so far, there is hope that this personalized cancer vaccine could change the landscape of cancer treatment, offering a new, effective approach for patients worldwide.

Advertisment
Chat with Dr. Medriva !